Publications by authors named "Taro Iguchi"

Claim this Profile
S
Summary of the clinical practice guideline for the management of urinary stones, third edition.
Katsuhito Miyazawa, Satoshi Yamaguchi, Taro Iguchi, Ippei Chikazawa, Takahiro Yasui

Int J Urol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer: A Secondary Analysis of the ARCHES Randomized Clinical Trial.
Arun A Azad, Daniel P Petrylak, Taro Iguchi, Neal D Shore, Arnauld Villers

JAMA Netw Open· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and ≥75 Years: ARCHES Post Hoc Analysis.
Francisco Gomez-Veiga, Russell Z Szmulewitz, Jeffrey Holzbeierlein, Arun A Azad, Taro Iguchi

Eur Urol Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Testosterone bounce predicts favorable prognoses for prostate cancer patients treated with degarelix.
Shuhei Kamada, Shinichi Sakamoto, Ryo Kinoshita, Xue Zhao, Tomohiko Kamasako, Taro Iguchi

Prostate· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES.
Andrew J Armstrong, Taro Iguchi, Arun A Azad, Arnauld Villers, Boris Alekseev

Eur Urol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[STUDY OF THE TRANSRECTAL PROSTATE BIOPSY IN KANAZAWA MEDICAL UNIVERSITY HOSPITAL, SUMMARY OF 20 YEARS].
Ippei Chikazawa, Shigeru Sugiki, Kenshiro Kunii, Chiharuko Ushimoto, Takeo Isii, Taro Iguchi

Nihon Hinyokika Gakkai Zasshi· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups.
Arnulf Stenzl, Russell Z Szmulewitz, Daniel Petrylak, Jeffrey Holzbeierlein, Arnauld Villers, Taro Iguchi

Prostate· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
Andrew J Armstrong, Arun A Azad, Taro Iguchi, Russell Z Szmulewitz, Daniel P Petrylak

J Clin Oncol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Descriptive study on burden and communication of fatigue among castration-resistant prostate cancer patients in Japan.
Taro Iguchi, Yusuke Nakamura, Takeshi Akiyama, Krishant Chand, Eric Yu

Curr Med Res Opin· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk.
Arun A Azad, Andrew J Armstrong, Antonio Alcaraz, Russell Z Szmulewitz, Daniel P Petrylak, Taro Iguchi

Prostate Cancer Prostatic Dis· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study.
Taro Iguchi, Go Kimura, Satoshi Fukasawa, Hiroyoshi Suzuki, Hiroji Uemura

Int J Urol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editorial Comment to Nonmetastatic castration-resistant prostate cancer treated with salvage focal brachytherapy after external beam radiotherapy.
Yukiyoshi Hirayama, Taro Iguchi

IJU Case Rep· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses.
Andrew J Armstrong, Neal D Shore, Russell Z Szmulewitz, Daniel P Petrylak, Jeffrey Holzbeierlein, Taro Iguchi

J Urol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply by Authors.
Andrew J Armstrong, Neal D Shore, Russell Z Szmulewitz, Daniel P Petrylak, Jeffrey Holzbeierlein, Taro Iguchi

J Urol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editorial Comment from Dr Hirayama and Dr Iguchi to Cranial nerve palsy caused by metastasis to the skull base in patients with castration-resistant prostate cancer: Three case reports.
Yukiyoshi Hirayama, Taro Iguchi

IJU Case Rep· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study.
Arnulf Stenzl, Curtis Dunshee, Ugo De Giorgi, Boris Alekseev, Taro Iguchi

Eur Urol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editorial Comment to Microscopic pulmonary tumor embolism from adenocarcinoma of the prostate.
Taro Iguchi, Akinori Minami

IJU Case Rep· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myeloid-derived suppressor cells are essential partners for immune checkpoint inhibitors in the treatment of cisplatin-resistant bladder cancer.
Yuji Takeyama, Minoru Kato, Satoshi Tamada, Yukari Azuma, Yasuomi Shimizu, Taro Iguchi

Cancer Lett· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: the OCUU-CRPC study.
Taro Iguchi, Satoshi Tamada, Minoru Kato, Sayaka Yasuda, Yuichi Machida

Int J Clin Oncol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.
Andrew J Armstrong, Russell Z Szmulewitz, Daniel P Petrylak, Jeffrey Holzbeierlein, Arnauld Villers, Taro Iguchi

J Clin Oncol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: a retrospective study.
Taro Iguchi, Satoshi Tamada, Minoru Kato, Sayaka Yasuda, Taiyo Otoshi

Int J Clin Oncol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study).
Taro Iguchi, Satoshi Tamada, Minoru Kato, Sayaka Yasuda, Takeshi Yamasaki

BMC Cancer· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Near infrared fluorescence imaging system for laparoscopic partial nephrectomy.
Takeshi Yamasaki, Satoshi Tamada, Minoru Kato, Taiyo Otoshi, Hisao Tanaka, Taro Iguchi

Can J Urol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time to progression to castration-resistant prostate cancer after commencing combined androgen blockade for advanced hormone-sensitive prostate cancer.
Satoshi Tamada, Taro Iguchi, Minoru Kato, Jumpei Asakawa, Kazuaki Kita

Oncotarget· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second-line treatment after sunitinib therapy in patients with renal cell carcinoma: a comparison of axitinib and mammalian target of rapamycin inhibitors.
Satoshi Tamada, Taro Iguchi, Minoru Kato, Sayaka Yasuda, Takeshi Yamasaki

Oncotarget· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis